https://www.ajmc.com/view/glasdegib-receives-priority-review-based-on-results-it-nearly-doubles-os-in-aml
Based on trial results that showed glasdegib, an investigational oral smoothened inhibitor, nearly doubled overall survival (OS) in patients with previously...
priority reviewglasdegibreceivesbasedresults